CHF Solutions (NSDQ:CHFS) announced today that Texas-based Baylor Scott & White Health began offering aquapheresis therapy using its Aquadex FlexFlow system.

Temple, Texas-based Baylor Scott & White Health is a major not-for-profit healthcare system in the state and among the largest in the U.S. The health system is now set to offer the Aquadex Flexflow at its Baylor Scott & White Medical Center in Temple.

Eden Prairie, Minn.–based CHF Solutions’ Aquadex FlexFlow system is designed to remove excess fluid from patients suffering from fluid overload. It is indicated for temporary (up to eight hours) of ultrafiltration treatment for patients who have failed diuretic therapy and for extended (more than eight hours) in patients who failed diuretic therapy and require hospitalization.

CHF Solutions said it has submitted an application for FDA 510(k) clearance to include pediatric patients who way 20kg or more as well.

“Fluid overload continues to be an issue to be managed in the acute and chronic care settings, and CHF Solutions’ Aquadex FlexFlow System has continually proven to be a viable and easy-to-maintain solution for managing these patients and improving their quality of life while reducing the cost of care,” said John Erb, CEO of CHF Solutions. “We are proud to provide products to Baylor Scott & White Medical Center -Temple and look forward to assisting its clinicians in the care of their fluid overloaded patients.”

In October 2019, the company announced that a U.S. Veterans Administration hospital in Florida received approval to begin an outpatient study using its Aquadex FlexFlow system.

Months earlier in March 2019, CHF Solutions touted data from a study that indicated that while the costs of ultrafiltration therapy were higher, fluid removal with ultrafiltration resulted in reduced hospital readmissions and cost savings of approximately $3,975, or 15%, when compared to diuretic therapy.

The company acquired the Aquadex device in 2016 for $5 million from Baxter (NYSE:BAX).